Last updated: February 19, 2026
This report details the patent TR201911086 filed in Turkey, examining its patent claims, scope, and the broader patent landscape. The analysis focuses on identifying key technological advancements and potential market implications relevant to pharmaceutical innovation and investment.
What is the Subject Matter of Patent TR201911086?
Patent TR201911086, titled "PROPYL [4-(3-ETHYL-5-HYDROXY-1-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL)PIPERAZIN-1-YL]ACETATE AND SALTS THEREOF," pertains to a specific chemical compound and its therapeutic applications. The primary subject matter is the compound propyl [4-(3-ethyl-5-hydroxy-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]acetate, and its pharmaceutically acceptable salts. This class of compounds is often investigated for their potential pharmacological activity.
What are the Core Claims of Patent TR201911086?
The patent's core claims define the legal protection afforded to the inventor. These claims are critical for understanding the scope of exclusivity.
Claim 1: Compound Protection
The most fundamental claim typically covers the novel compound itself. In this case, it is the specific chemical entity: propyl [4-(3-ethyl-5-hydroxy-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]acetate. This claim provides the broadest protection, encompassing the molecule irrespective of its use.
Claim 2: Pharmaceutically Acceptable Salts
This claim extends protection to various pharmaceutically acceptable salts of the compound identified in Claim 1. Salts can be used to improve a drug's solubility, stability, or bioavailability. Protecting these forms is standard practice in pharmaceutical patenting.
Claim 3: Pharmaceutical Compositions
Claim 3 likely covers pharmaceutical compositions containing the active compound or its salts. This would include formulations such as tablets, capsules, injectables, or other dosage forms, along with excipients.
Claim 4: Method of Treatment
A common claim in drug patents is the method of using the compound for treating specific diseases. While the exact diseases are not detailed in the title, such claims typically specify a therapeutic indication. For instance, it could be related to conditions where phosphodiesterase (PDE) inhibition is beneficial.
Claim 5: Specific Use or Intermediate
Depending on the patent's strategy, further claims might cover specific therapeutic uses, a particular dosage regimen, or an intermediate compound used in the synthesis of the active pharmaceutical ingredient (API).
Table 1: Summary of Potential Claim Types for TR201911086
| Claim Type |
Description |
| Compound |
The novel chemical entity propyl [4-(3-ethyl-5-hydroxy-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]acetate. |
| Salts |
Pharmaceutically acceptable salts of the claimed compound. |
| Pharmaceutical Compositions |
Formulations containing the compound or its salts, with pharmaceutically acceptable carriers. |
| Method of Treatment |
Use of the compound or its salts for treating a specific medical condition. |
| Specific Therapeutic Application |
A more refined indication or specific application of the compound's therapeutic effect. |
Note: The precise wording and scope of each claim are defined in the patent document itself. This table presents typical claim categories for such a patent.
What is the Technological Scope of Patent TR201911086?
The technological scope of the patent is defined by the chemical structure and its implied mechanism of action. The pyrazolo[3,4-d]pyrimidine core is a known scaffold in medicinal chemistry, often associated with inhibiting various enzymes.
Chemical Structure and Class
The compound belongs to the pyrazolo[3,4-d]pyrimidine chemical class. This heterocyclic system is a structural isomer of purine and is found in various biologically active molecules. Derivatives of this scaffold have been developed as inhibitors of enzymes such as phosphodiesterases (PDEs), protein kinases, and other targets relevant to inflammation, cardiovascular disease, and oncology.
Implied Mechanism of Action
Based on the chemical structure and prior art associated with pyrazolo[3,4-d]pyrimidines, it is highly probable that this compound is designed to inhibit a specific enzyme. Phosphodiesterase (PDE) inhibition is a common target for this structural class. For example, sildenafil (Viagra), a PDE5 inhibitor, also features a pyrazolo[3,4-d]pyrimidine core. If TR201911086 targets PDEs, its therapeutic applications could include erectile dysfunction, pulmonary arterial hypertension, or other conditions influenced by cyclic nucleotide signaling.
Synthesis and Manufacturing Process
While the patent's title does not explicitly detail the synthesis, the claims and description sections would typically outline a synthetic route. This would define the technological scope concerning the manufacturing process, potentially including specific reagents, reaction conditions, and purification methods. Protection may also extend to novel intermediates or specific synthetic pathways that are inventive.
Potential Therapeutic Areas
The technological scope also encompasses the intended therapeutic areas. Without explicit detail in the title, potential areas include:
- Cardiovascular diseases (e.g., pulmonary arterial hypertension, heart failure)
- Urological disorders (e.g., erectile dysfunction)
- Inflammatory conditions
- Oncology (depending on the specific enzyme targeted)
What is the Patent Landscape for Similar Technologies in Turkey?
Analyzing the patent landscape provides context for the novelty and inventiveness of TR201911086. This involves identifying existing patents for similar compounds, mechanisms of action, or therapeutic uses within Turkey's patent system.
Existing Patents for Pyrazolo[3,4-d]pyrimidine Derivatives
The pyrazolo[3,4-d]pyrimidine scaffold is a well-established area of pharmaceutical research. Numerous patents exist globally and likely within Turkey for compounds based on this core structure, targeting various indications. Companies like Pfizer, Bayer, and others have significant patent portfolios related to PDE inhibitors and other drugs utilizing this scaffold.
Identification of Competitor Patents
A comprehensive landscape analysis would involve searching the Turkish Patent and Trademark Office (Türk Patent) database for:
- Patents claiming compounds with similar structural features.
- Patents claiming the use of pyrazolo[3,4-d]pyrimidine derivatives for specific therapeutic areas.
- Patents covering manufacturing processes for related compounds.
Table 2: Key Parameters for Landscape Analysis
| Parameter |
Description |
Data Source Example |
| Patent Filing Dates |
To establish prior art and assess novelty. |
Türk Patent database search by date range. |
| Patent Applicant/Assignee |
To identify key players and potential competitors. |
Türk Patent database search by assignee name. |
| International Patent Classes (IPC) |
To categorize technologies and identify related patent families. |
IPC codes related to organic chemistry, pharmaceuticals. |
| Keywords |
Specific chemical names, therapeutic indications, mechanisms of action. |
Keyword searches within patent abstracts and claims. |
| Claim Scope Analysis |
To understand the breadth of protection sought by competitors. |
Detailed review of competitor patent claims. |
| Patent Status (Granted/Expired) |
To determine active market exclusivity. |
Türk Patent database status indicator. |
Freedom to Operate (FTO) Considerations
For any company looking to develop or market a product related to TR201911086, a Freedom to Operate (FTO) analysis is crucial. This involves determining if the proposed activities (e.g., manufacturing, selling, using the compound) would infringe any existing valid patents in Turkey. The analysis would assess:
- The claims of TR201911086.
- The claims of other relevant patents in the Turkish market.
- The potential overlap in chemical structures, methods of use, and manufacturing processes.
Patent Exclusivity in Turkey
The term of a patent in Turkey is generally 20 years from the filing date, subject to payment of annual renewal fees [1]. For patent TR201911086, filed in 2019, the potential expiry date is around 2039, assuming all maintenance fees are paid. This timeline is a critical factor for investment and market entry strategies.
Generic Competition
Once a patent expires, generic manufacturers can enter the market. The patent landscape analysis should also consider the timing of competitor patent expiries to anticipate future generic competition.
Strategic Implications for R&D and Investment
The analysis of TR201911086 provides several strategic implications for pharmaceutical companies, R&D departments, and investors.
Novelty and Inventiveness Assessment
The patent's claims define what is considered novel and inventive by the Turkish Patent Office. Its validity can be challenged if prior art demonstrating a lack of novelty or inventiveness is discovered. Companies considering challenging this patent would focus on identifying such prior art.
Market Exclusivity and Opportunity
The duration of patent protection offers a period of market exclusivity. For the innovator, this is an opportunity to recoup R&D investments and establish market share. For competitors, it defines the timeline for market entry with generic alternatives or biosimilars (if applicable).
Licensing and Partnership Opportunities
If TR201911086 is held by a company with a strong patent portfolio, it may present licensing opportunities for other pharmaceutical firms seeking access to the technology for development or commercialization.
Investment Due Diligence
For investors, a thorough understanding of this patent is vital for due diligence. This includes:
- Assessing the therapeutic potential of the claimed compound.
- Evaluating the strength and breadth of the patent claims.
- Analyzing the competitive patent landscape and potential FTO issues.
- Estimating the market size and potential revenue during the exclusivity period.
Diversification of Drug Pipelines
Companies with existing pipelines in areas like cardiovascular or urological diseases might view this patent as an opportunity for diversification or to strengthen their position in a particular therapeutic area.
Conclusion
Patent TR201911086 protects a specific chemical compound within the pyrazolo[3,4-d]pyrimidine class. Its claims likely cover the compound, its salts, pharmaceutical compositions, and methods of treatment. The technological scope points towards potential applications in areas where enzyme inhibition, such as PDE inhibition, is therapeutically relevant. The broader patent landscape for similar compounds in Turkey is active, necessitating careful FTO analysis and consideration of competitor patent portfolios. The patent's 20-year term from 2019 defines a period of market exclusivity, impacting R&D strategies, investment decisions, and future market entry plans for generic manufacturers.
Key Takeaways
- Patent TR201911086 claims protection for the compound propyl [4-(3-ethyl-5-hydroxy-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]acetate and its salts.
- The patent's scope likely extends to pharmaceutical compositions and methods of treatment, potentially targeting enzyme inhibition (e.g., PDEs).
- The pyrazolo[3,4-d]pyrimidine scaffold is well-represented in existing pharmaceutical patents, requiring thorough landscape analysis.
- Market exclusivity in Turkey is granted for 20 years from the filing date, setting a critical timeframe for strategic planning.
- Freedom to Operate (FTO) analysis is essential for any entity considering activities related to the patented compound in Turkey.
Frequently Asked Questions
-
What specific diseases can the compound in TR201911086 potentially treat?
The patent title does not specify diseases, but the chemical structure suggests potential applications related to enzyme inhibition, such as phosphodiesterase (PDE) inhibition. This could include conditions like erectile dysfunction or pulmonary arterial hypertension. A detailed review of the patent's description section is required for definitive information.
-
How long is the patent protection for TR201911086 valid in Turkey?
In Turkey, patents are generally valid for 20 years from the filing date. For TR201911086, filed in 2019, protection is expected to last until approximately 2039, provided all annual renewal fees are paid.
-
What is the importance of claiming "salts thereof" in a drug patent?
Claiming pharmaceutically acceptable salts is important because salts can significantly alter a drug's properties, such as solubility, stability, and bioavailability. Protecting these forms ensures broader market exclusivity for the active compound.
-
Can a generic company launch a product that is structurally similar but not identical to the compound in TR201911086?
Whether a structurally similar compound infringes TR201911086 depends on the specific wording and scope of its claims. Patent claims are interpreted based on their language and legal precedent. A Freedom to Operate (FTO) analysis is necessary to assess potential infringement risks for any new compound.
-
Where can I find the full text and detailed claims of patent TR201911086?
The full text of patent TR201911086 can typically be accessed through the official database of the Turkish Patent and Trademark Office (Türk Patent) or through commercial patent databases that index Turkish national patents.
Citations
[1] Turkish Patent and Trademark Office. (n.d.). Patent Application and Registration Procedures. Retrieved from https://www.turkpatent.gov.tr/ (Note: Direct URL to specific procedural documents may change; refer to the main website for current information).
